Jieti Medical

Jieti Medical (阶梯医疗) is a Chinese invasive brain-computer interface company co-founded by Zhengtuo Zhao and Dr. Li Xue, a researcher at the Chinese Academy of Sciences' Center for Excellence in Brain Science . It works on the hardest end of BCI — as Li put it in a Qiming Venture Partners piece, invasive interfaces are "the most difficult direction in BCI, and also the one with the highest ceiling," with the company openly aiming to rival Neuralink . In Q1 2025 its self-developed invasive BCI system completed China's first prospective clinical trial of such a system at Huashan Hospital affiliated with Fudan University, and it subsequently raised a 350 million yuan Series B co-led by Qiming Venture Partners . Qiming's William Hu has singled out the investment as a bet that BCI will be "the next sector of meaningful scale," while Source Code Capital's Yungang Huang also counts Jieti among his deals .